Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Expedia Group Inc (EXPE) vs GSK plc (GSK) Price & Performance

Expedia Group IncTrade

Price performance (Past 24H)

Key statistics

Expedia Group Inc vs GSK plc — how do they compare? Expedia Group Inc trades at $326.02 (market cap $38.53B), while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc is far larger — about 2.7× Expedia Group Inc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.

EXPEGSK
Market Cap
$38.53B$102.60B
Sector
Consumer CyclicalHealth
52-Week High
$321.07$61.18
52-Week Low
$188.51$38.22
Enterprise Value
$37.09B$123.04B
Dividend Yield
0.6%3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Expedia Group Inc

Expedia Group (EXPE) trades at $328.08, up 4.48% on the day, reflecting strong momentum after Q2 2026 earnings beat. The stock shows a bullish technical trend with moving averages aligned positively, while fundamentals highlight robust revenue growth, expanding margins, and consistent earnings outperformance. Recent news emphasizes AI integration and B2B growth driving upward guidance revisions.

Outlook remains favorable with raised full-year revenue guidance and solid cash flow generation, though elevated valuation multiples and overbought RSI levels near-term pose risks. Analyst consensus leans neutral with a $322.95 price target slightly below current levels, suggesting cautious optimism amid execution and competitive pressures.

GSK plc

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Expedia Group Inc

Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.

Read more on EXPE

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK